ArticleMolecular cancer therapeutics2025

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.

Melissa L Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.